Secure Asset Management LLC Decreases Position in Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Secure Asset Management LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 6.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,808 shares of the company’s stock after selling 2,061 shares during the period. Merck & Co., Inc. comprises 1.3% of Secure Asset Management LLC’s portfolio, making the stock its 17th largest position. Secure Asset Management LLC’s holdings in Merck & Co., Inc. were worth $2,298,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Catalyst Private Wealth LLC bought a new stake in shares of Merck & Co., Inc. in the third quarter worth $25,000. Flagship Private Wealth LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth $27,000. Financial Avengers Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth $28,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth $29,000. Finally, Curi Capital acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth $29,000. Institutional investors and hedge funds own 72.86% of the company’s stock.

Merck & Co., Inc. stock opened at $76.66 on Friday. Merck & Co., Inc. has a 52-week low of $71.71 and a 52-week high of $87.80. The firm has a fifty day moving average of $75.60 and a 200-day moving average of $78.75. The firm has a market capitalization of $193.98 billion, a P/E ratio of 16.96, a PEG ratio of 1.89 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.30 and a debt-to-equity ratio of 0.90.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.38 by ($0.06). The firm had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.65 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. Merck & Co., Inc.’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.16 earnings per share. On average, research analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 7th. Stockholders of record on Monday, March 15th were given a $0.65 dividend. The ex-dividend date of this dividend was Friday, March 12th. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.39%. Merck & Co., Inc.’s payout ratio is currently 50.10%.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Merck & Co., Inc. has an average rating of “Buy” and a consensus price target of $96.27.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.

Further Reading: Correction

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with's FREE daily email newsletter.